Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

February 10, 2016 6:04 AM ET


Company Overview of NuView Life Sciences, Inc.

Company Overview

NuView Life Sciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of diagnostic imaging probes and disease specific biomarkers used in the field of molecular imaging. Its clinical stage pipeline includes various proprietary products for diagnosing cancer and heart disease. The company was incorporated in 2004 and is based in Park City, Utah.

1107 Snowberry Street

Park City, UT 84098

United States

Founded in 2004





Key Executives for NuView Life Sciences, Inc.

Chairman and Chief Executive Officer
Age: 65
Compensation as of Fiscal Year 2015.

NuView Life Sciences, Inc. Key Developments

NuView Life Sciences Enters Global Licensing Agreement with Otsuka Pharmaceutical

NuView Life Sciences, Inc. announced entry into an exclusive global licensing and collaboration agreement with Otsuka Pharmaceutical Co. Ltd. (Otsuka) to further develop and commercialize NuView's investigative genomic-based diagnostic biomarker to detect cancers of the breast and prostate. The agreement also includes all other future diagnostic-imaging applications. NuView retains all rights for the VPAC1 compound for in-vivo therapeutic delivery and in-vitro urine screen applications. Under the terms of the agreement, Otsuka will provide funding for all future clinical trials and commercialization of the VPAC1 biomarker worldwide. Otsuka intends to utilize NuView's manufacturing subsidiary, US Radiopharmaceuticals, Inc., to meet requirements for clinical trials through future commercialization upon approval. The two companies anticipate initiating a Phase I trial in the U.S. in the coming months. The VPAC1 biomarker originated at Thomas Jefferson University (TJU) Philadelphia, PA. When regulatory approval is received, the VPAC1 biomarker will be utilized as a target-specific radiopharmaceutical in diagnostic Positron Emission Tomography (PET) imaging procedures.

Similar Private Companies By Industry

Company Name Region
Sorbent Therapeutics, Inc. United States
Merz, Incorporated United States
E. Claiborne Robins Company, Inc. United States
AquaCap, Inc. United States
Archimedes Pharma US Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact NuView Life Sciences, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at